JCP Weekly September 18, 2018

Original Research

Metabolic Syndrome Predicts Relapse in Schizophrenia

Cardiovascular diseases are the primary cause of mortality in individuals with schizophrenia, yet no study has yet explored the impact of metabolic syndrome on schizophrenia relapse. This study explored the effect that several risk factors—including metabolic syndrome—have on schizophrenia relapse.

DOI: 10.4088/JCP.17m12007 | Posted: 09/18/2018


Meta-Analysis of Clozapine for Tardive Dyskinesia

Tardive dyskinesia, a side effect of antipsychotics, is a persistent and disabling problem among patients with schizophrenia. Could a switch to clozapine help? This meta-analysis looks at 16 studies to evaluate the current evidence.

DOI: 10.4088/JCP.17r11852 | Posted: 09/18/2018

Original Research

Comparing the Effectiveness of Medications for PTSD

When choosing among agents for treating PTSD, which one should you pick? Fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine have all shown efficacy. This large retrospective VA study compared the treatments on the basis of PTSD Checklist scores to see if they yielded different outcomes.

DOI: 10.4088/JCP.18m12145 | Posted: 09/18/2018

See past JCP Weekly